Eszopiclone Articles
Eisai gets Lunesta approval in Japan, launches Fostoin
20 January 2012
Lupin settles Lunesta patent litigation with Dainippon Sumitomo; Par Pharma starts shipping generic Rythmol and Lotrel
5 January 2011
Japan’s Dainippon Sumitomo makes $2.6 billion bid for Sepracor
3 September 2009
Sepracor's 1st-qtr revenues jump 3%
5 May 2009
Mylan group sued over for first-to-file ANDAs
27 March 2009
Lunesta misses Ph II efficacy endpoints
16 March 2009
Japan stock market week to August 25, 2008
1 September 2008
DEA block to US e-Rx adoption set to end
30 June 2008
GSK licenses Speracor's insomnia drug
17 September 2007
Sanofi and Actelion will dominate insomnia market by 2016
3 September 2007
Sepracor and Eisai to sell eszopiclone in Japan
6 August 2007
Japan stock market week to July 30, 2007
6 August 2007
Sepracor files Lunivia MAA with EMEA
6 August 2007
Lilly to buy Hypnion for access to drugs
12 March 2007
Takeda R&D meeting focuses on insomnia treatment Rozeram
1 August 2005
Sanofi-Aventis: is growth slowing?
1 August 2005
Sanofi-Aventis' Ambien "approvable"
18 April 2005
Sepracor's Lunesta now available in the USA
18 April 2005
Second Lunesta trial confirms efficacy
18 April 2005
Launch of Sepracor's Lunesta delayed
17 January 2005
Sepracor's Lunesta approved by FDA
20 December 2004
Sanofi's bid for Aventis cleared by FTC
2 August 2004
FDA accepts new Estorra filing
26 July 2004
Sepracor resubmits Estorra NDA
21 June 2004
Sepracor's Estorra approvable, says FDA
8 March 2004
Sepracor's Estorra effective: long-term study
2 June 2003
Sepracor seeks US OK for eszopiclone
10 February 2003
Showing 1-36 of 36 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
